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A B S T R A C T
Background
Acute sinusitis is the inflammation and swelling of the nasal and paranasal mucous membranes and is a common reason for patients
to seek primary care consultations. The related impairment of daily functioning and quality of life is attributable to symptoms such as
facial pain and nasal congestion.
Objectives
To assess the effects of systemic corticosteroids on clinical response rates and to determine adverse effects and relapse rates of systemic
corticosteroids compared to placebo or standard clinical care in children and adults with acute sinusitis.
Search methods
We searched CENTRAL (2014, Issue 1), MEDLINE (1966 to February week 1, 2014) and EMBASE (January 2009 to February
2014).
Selection criteria
Randomised controlled trials (RCTs) comparing systemic corticosteroids to placebo or standard clinical care for patients with acute
sinusitis.
Data collection and analysis
Two review authors independently assessed the methodological quality of the trials and extracted data.
Main results
Five RCTs with a total of 1193 adult participants met our inclusion criteria. We judged methodological quality to be moderate in
four trials and high in one trial. Acute sinusitis was defined clinically in all trials. However, the three trials performed in ear, nose and
throat (ENT) outpatient clinics also used radiological assessment as part of their inclusion criteria. All participants were assigned to
either oral corticosteroids (prednisone 24 mg to 80 mg daily or betamethasone 1 mg daily) or the control treatment (placebo in four
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trials and non-steroidal anti-inflammatory drugs (NSAIDs) in one trial). In four trials antibiotics were prescribed in addition to oral
corticosteroids or control treatment, while one trial investigated the effects of oral corticosteroids as a monotherapy.
When combining data from the five trials, participants treated with oral corticosteroids were more likely to have short-term resolution
or improvement of symptoms than those receiving the control treatment: at days three to seven (risk ratio (RR) 1.3, 95% confidence
interval (CI) 1.1 to 1.6; risk difference (RD) 17%, 95% CI 6% to 29%) and at days four to 14 (RR 1.2, 95% CI 1.0 to 1.5; RD
14%, 95% CI 1% to 27%). A sensitivity analysis including the four trials with placebo as a control treatment showed similar results
but with a lesser effect size: at days three to seven (RR 1.2, 95% CI 1.1 to 1.3; RD 11%, 95% CI 4% to 17%) and days four to 14
(RR 1.1, 95% CI 1.0 to 1.2; RD 8%, 95% CI 2% to 13%). Statistical heterogeneity was high for many analyses. Subgroup analyses
revealed that corticosteroid monotherapy had no beneficial effects. Furthermore, scenario analysis showed that outcomes missing from
the trial reports might have introduced attrition bias (a worst-case scenario showed no statistically significant beneficial effect of oral
corticosteroids). No trial reported effects on relapse or recurrence rates. Reported side effects in patients treated with oral corticosteroids
were mild (nausea, vomiting, gastric complaints) and did not significantly differ from those receiving placebo.
Authors’ conclusions
Oral corticosteroids as a monotherapy appear to be ineffective for adult patients with clinically diagnosed acute sinusitis. Current data
on the use of oral corticosteroids as an adjunctive therapy to oral antibiotics are limited: almost all trials are performed in secondary care
settings and there is a significant risk of bias. This limited evidence suggests that oral corticosteroids in combination with antibiotics
may be modestly beneficial for short-term relief of symptoms in acute sinusitis, with a number needed to treat to benefit of seven
for resolution or symptom improvement. A large primary care factorial trial is needed to establish whether oral corticosteroids offer
additional benefits over antibiotics in acute sinusitis.
P L A I N L A N G U A G E S U M M A R Y
Steroidal anti-inflammatory medication given by mouth or injection for acute sinusitis
Review question
We reviewed the evidence about the effect of steroidal anti-inflammatory medication (i.e. corticosteroids) given by mouth or injection
(i.e. systemically) compared to placebo or standard clinical care on acute attacks of nose and sinus complaints (i.e. acute sinusitis) in
children and adults.
Background
Acute sinusitis may be caused directly by viral or bacterial infections and by the body’s inflammatory response to these infections.
Therefore, anti-inflammatory treatments may be effective in treating this condition. Earlier reviews found only modest beneficial effects
of corticosteroids given by nasal spray. It is unclear if this is because the intranasal corticosteroids did not actually reach the (blocked)
nasal passages or because anti-inflammatory drugs do not work.
Study characteristics
This review included evidence up to 19 February 2014. Five trials involving 1193 participants aged 15 years and older with acute sinusitis
were included. In four trials participants received either antibiotics plus oral corticosteroids or antibiotics plus control treatment, while
one trial assessed the effects of corticosteroids alone. Information on symptom relief was only available for the short term (two weeks
or less) and no trial reported on relapse rates. No data for children were available.
Key outcomes
After combining trial findings, the results suggest that adults treated with oral corticosteroids plus antibiotics are more likely to have
short-term symptom relief than those receiving a placebo or non-steroidal anti-inflammatory drug plus antibiotics. To benefit a single
person, seven would need to receive treatment (number needed to treat to benefit). The trial assessing the effects of oral corticosteroids
without antibiotics found no beneficial effects compared to placebo. Reported side effects in patients treated with oral corticosteroids
were mild (nausea, vomiting, gastric complaints) and did not significantly differ from those receiving placebo.
Quality of the evidence
We judged the quality of the evidence for oral corticosteroids plus antibiotics to be low (further research is very likely to have an
important impact on our confidence in the effect estimate and is likely to change the estimate) as the evidence is derived from four
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trials, including a relatively low number of participants, with a substantial risk of bias. Evidence of the effect of oral corticosteroids
without antibiotics is derived from only one high-quality trial and we therefore judged the quality to be moderate (further research is
likely to have an important impact on our confidence in the effect estimate and may change the estimate).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oral corticosteroids versus placebo or NSAID for acute sinusitis
Patient or population: pat ients with acute sinusit is
Settings: primary and secondary care
Intervention: oral cort icosteroids versus placebo or NSAID
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Oral corticosteroids
versus placebo or
NSAID
Proportion of patients
with resolution or im-
proved symptoms at
days 3 to 7
Study population RR 1.33
(1.09 to 1.62)
1043
(5 studies)
⊕⊕⊕©
moderate1
544 per 1000 724 per 1000
(593 to 882)
Moderate
476 per 1000 633 per 1000
(519 to 771)
Proportion of patients
with resolution or im-
proved symptoms at
days 3 to 7 - Co-treat-
ment with ant ibiot ics
Study population RR 1.40
(1.08 to 1.81)
869
(4 studies)
⊕⊕©©
low2,3
541 per 1000 758 per 1000
(585 to 980)
Moderate
474 per 1000 664 per 1000
(512 to 858)
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Proportion of patients
with resolution or im-
proved symptoms at
days 3 to 7 - Cort icos-
teroid monotherapy
Study population RR 1.12
(0.87 to 1.44)
174
(1 study)
⊕⊕⊕©
moderate4
558 per 1000 625 per 1000
(486 to 804)
Moderate
558 per 1000 625 per 1000
(485 to 804)
Proportion of patients
with resolution or im-
proved symptoms at
days 4 to 14
Study population RR 1.23
(1.02 to 1.49)
1116
(5 studies)
⊕⊕⊕©
moderate1
657 per 1000 808 per 1000
(670 to 978)
Moderate
651 per 1000 801 per 1000
(664 to 970)
Proportion of patients
with resolution or im-
proved symptoms at
days 4 to 14 - Co-treat-
ment with ant ibiot ics
Study population RR 1.32
(1.04 to 1.68)
945
(4 studies)
⊕⊕©©
low2,3
632 per 1000 834 per 1000
(657 to 1000)
Moderate
564 per 1000 744 per 1000
(587 to 948)
Proportion of patients
with resolution or im-
proved symptoms at
days 4 to 14 - Cort icos-
teroid monotherapy
Study population RR 0.99
(0.85 to 1.16)
171
(1 study)
⊕⊕⊕©
moderate4
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798 per 1000 790 per 1000
(678 to 925)
Moderate
798 per 1000 790 per 1000
(678 to 926)
Adverse events No serious drug-related adverse events were reported in the 5 trials.
Adverse events were lim ited and mild (see Table 1) with no dif ferences
between the systemic cort icosteroid and the control treatment groups
1193
(5 studies)
⊕⊕⊕©
moderate5
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Methodological quality was judged moderate in four trials and high in one trial.
2Methodological quality of the four trials was judged moderate.
3Largest benef icial ef fect observed in one trial that used non-steroidal ant i-inf lammatory drug (NSAID) as control treatment.
4Only one trial with a wide conf idence interval; unknown whether a larger trial would have been able to detect a (small)
benef icial ef fect of oral cort icosteroids as a monotherapy.
5Trials not powered to detect (small) dif f erences in adverse events between those receiving cort icosteroids or control
treatment. However, none of the trials reported serious adverse events nor sinusit is-related complicat ions.
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B A C K G R O U N D
Acute sinusitis is an important reason for primary care consulta-
tions, with typically 50 cases seen by a primary care doctor an-
nually (Ashworth 2005; Kuyvenhoven 2006). This condition is
associated with symptoms such as facial pain, headache and nasal
congestion, which can be unpleasant for many people (Meltzer
2004). As a consequence, patients may seek medical attention in
order to relieve symptoms and shorten the illness duration. Pa-
tients’ misconceptions about the effectiveness of antibiotics in vi-
ral infections (Cals 2007) and physicians’ overestimation of pa-
tients’ expectations towards antibiotic prescriptions (Akkerman
2005b;Welschen 2004), along with the lack of specific knowledge
about respiratory tract infections (Akkerman 2005a), are proba-
bly the main reasons for high antibiotic prescription rates in daily
practice, ranging from approximately 60% in the Netherlands
(Venekamp 2012b) to 92% in the United Kingdom (Ashworth
2005). However, a recent systematic review and a meta-analysis of
individual data from randomised controlled trials (RCTs) showed
that antibiotics are of limited use in patients with acute sinusitis
(Ahovuo-Saloranta 2011; Young 2008). Acute sinusitis is there-
fore associated with both high direct and indirect healthcare costs
and contributes to antimicrobial resistance.
Description of the condition
Acute sinusitis is defined as inflammation and swelling of the nasal
and paranasal mucous membranes (Fokkens 2012; Snow 2001). It
is thought that this mucosal swelling leads to obstruction of sinus
openings and impairment of mucous drainage, sinus ventilation
and mucociliary clearance, leading to the characteristic signs and
symptoms of acute sinusitis such as purulent nasal discharge, nasal
obstruction, reduction or loss of smell, headache, facial pain/pres-
sure and/or dental pain (Fokkens 2012). In primary care settings,
diagnosing acute sinusitis is usually based on signs and symptoms,
since the diagnostic value of laboratory measurements (such as C-
reactive protein, erythrocyte sedimentation rate and white blood
cell count) is low (Hansen 1995; Lindbaek 1996) and imaging
(such as sinus X-ray and sinus ultrasound) leads to a high num-
ber of false positive and negative results (Laine 1998; Van Duijn
1992). The use of more advanced and invasive diagnostic tools
such as nasal endoscopy, computed tomography (CT) scanning
and sinus puncture are limited to secondary or tertiary care set-
tings.
There is considerable debate about the aetiology of clinically di-
agnosed acute sinusitis. The condition was thought to be due to a
bacterial infection of the paranasal sinuses (Piccirillo 2004). How-
ever, themajority of cases of acute sinusitis are likely to be caused by
viral pathogens, since only 0.5% to 2% of viral upper respiratory
tract infections are complicated by bacterial sinusitis (Berg 1986;
Gwaltney 1996). Moreover, the results of a systematic review of
RCTs with antibiotics have demonstrated only modest beneficial
effect sizes (Ahovuo-Saloranta 2011), and a recent meta-analysis
of individual patient data confirms that antibiotics are of limited
use in clinically diagnosed acute sinusitis, even when patients do
report signs and symptoms for 10 days or longer (Young 2008).
As a consequence, acute inflammation of the paranasal mucosa
due to (viral) pathogens might be the predominant common
path in the causation of clinically diagnosed acute sinusitis (Snow
2001; Winstead 2003). Additionally, some studies suggest that
non-infectious processes such as allergic inflammation and lo-
cal eosinophilia may also play an important role (Baroody 2008;
Kirtsreesakul 2004). Therefore, it is possible that anti-inflamma-
tory therapy could provide attenuation of the host inflammatory
response, leading to reductions in mucosal oedema and enhanced
sinus clearance.
Description of the intervention
Corticosteroids inhibit transcription of pro-inflammatory media-
tors in human airway endothelial cells (Mygind 2001) and could
potentially act as anti-inflammatory and decongestant agents. As
a consequence, the use of corticosteroids might have beneficial ef-
fects in patients with common cold and acute sinusitis. A recent
Cochrane review demonstrated that current limited evidence does
not support the use of intranasal corticosteroids for symptomatic
relief from the common cold (Hayward 2012b). Recent system-
atic reviews have assessed the role of intranasal but not systemic
corticosteroids for acute sinusitis (Hayward 2012a; Zalmanovici
2011). One review found that for every 100 patients treated with
intranasal corticosteroids, seven additional patients had complete
or marked symptom relief at 15 to 21 days (number needed to
treat to benefit (NNTB) = 15) (Zalmanovici 2011), while the
other review reported more or less similar results (for every 100
patients treated, eight additional patients had improvement or res-
olution of symptoms at 14 to 21 days, NNTB = 13) (Hayward
2012a). However, it was suggested that the effects of intranasal
corticosteroids may be greater with high doses and with courses of
21 days’ duration. In one of the included trials therapy tended to
be more effective in mild than in severe cases, leading to the sug-
gestion that thick secretions and severe inflammation in the nasal
passages limited the effective topical delivery of the corticosteroids
(Williamson 2007).
How the intervention might work
Systemic administration of corticosteroidsmight allowmore effec-
tive delivery of corticosteroids to the nasal and paranasal mucosa
than topical corticosteroids, providing increased anti-inflamma-
tory effects. This could lead to a reduction in nasal oedema, mucus
production and sinus blockage, which could result in symptomatic
relief. Systemic corticosteroids (alone or as adjunctive treatment)
are effective at reducing the severity of some acute respiratory tract
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infections such as croup (Russell 2011) and sore throat (Hayward
2009), aswell as inflammatory conditions such as asthma and exac-
erbations of chronic obstructive airways disease (Schweiger 2010).
When implementing systemic corticosteroid therapy in practice,
physicians should be aware of the absence of specific contraindi-
cations including (active) peptic ulcer disease, history of depres-
sion or psychosis and immunodeficiency. Immunocompromised
patients have an increased risk of bacterial (super)infection during
viral (respiratory tract) infections and the use of systemic corticos-
teroids might further enhance this probability.
Why it is important to do this review
There has not been a systematic review of systemic corticosteroids
for acute sinusitis. The beneficial effects of intranasal corticos-
teroids are modest but it is unclear if this is due to poor deliv-
ery of corticosteroids due to blocked nasal passages, or lack of an
anti-inflammatory effect in acute sinusitis. This systematic review
examines the effects of systemic corticosteroids in patients with
acute sinusitis in order to provide a more definite answer on the
use of corticosteroids for this condition.
O B J E C T I V E S
To assess the effects of systemic corticosteroids on clinical response
rates and to determine adverse effects and relapse rates of systemic
corticosteroids compared to placebo or standard clinical care in
children and adults with acute sinusitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs comparing systemic corticosteroids to placebo or standard
clinical care.
Types of participants
Children and adults with acute sinusitis.
Acute sinusitis was defined by clinical diagnosis alone, or con-
firmed by additional radiological or nasal endoscopic examina-
tion. We excluded studies examining participants with a diagnosis
of chronic sinusitis (defined as more than 12 weeks’ duration) or
other clear diagnoses (for example, common cold, nasal polypo-
sis).
Types of interventions
Studies which used systemic corticosteroids versus placebo or stan-
dard clinical care in the control group. We included trials of corti-
costeroids delivered orally, or parenterally by intravenous or intra-
muscular injection. We excluded trials of corticosteroids delivered
by the intranasal route or by inhalation.
We included trials reporting combined interventions (for example,
co-treatment with antibiotics) if they allowed a direct comparison
between the systemic corticosteroid and the control group and
were unconfounded. By unconfounded, we mean studies where
the two groups were not treated differently, except for the delivery
of systemic corticosteroids to one group.
Types of outcome measures
Primary outcomes
1. Proportion of participants with resolution or improvement
of any patient-related symptoms, including total change in
clinical status, measured at two time points - short-term (two
weeks or less) or long-term (more than two weeks).
Secondary outcomes
1. Time to resolution of symptoms.
2. Bacteriological cure and relapse rates.
3. Adverse events.
Search methods for identification of studies
Electronic searches
For this 2014 update of our 2011 review (Venekamp 2011),
we searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (2014, Issue 1), which includes the Acute Respi-
ratory Infections (ARI) Group’s Specialised Register, MEDLINE
(1966 to February week 1, 2014) and EMBASE (January 2009
to February 2014). There were no language or publication restric-
tions.
We combined the MEDLINE search with the Cochrane Highly
Sensitive Search Strategy for identifying randomised trials in
MEDLINE: sensitivity- and precision-maximising version (2008
revision) Ovid format (Lefebvre 2011). See Appendix 1 for the
MEDLINE and CENTRAL search strategy and Appendix 2 for
the EMBASE search strategy.
Searching other resources
To increase the yield of relevant studies, we inspected the reference
lists of all identified studies and reviews. We searched theDatabase
of Reviews of Effects (DARE) (Issue 1 of 4, January 2014) and the
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NHS Health Economics Database (EED) (Issue 1 of 4, January
2014), part ofThe Cochrane Library, www.thecochranelibrary.com
(accessed 19 February 2014). We also searched the trials registries
ClinicalTrials.gov and WHO ICTRP for completed and ongoing
trials (accessed 19 February 2014).
Data collection and analysis
Selection of studies
In the first publication of this review (Venekamp 2011), two re-
view authors (RV,MT) independently screened titles and abstracts
from the electronic searches and reviewed the full text of the po-
tentially relevant titles and abstracts against the inclusion and ex-
clusion criteria. For this 2014 update, two review authors (RV,
PG) independently completed these tasks.
Data extraction and management
In the first publicationof this review (Venekamp 2011), two review
authors (RV, MT) extracted data from the included trials and
resolved disagreements by discussion. For this 2014 update, two
review authors (GH, PG) extracted data from the included trials
and resolved disagreements by discussion. We entered data into
RevMan 2012.We extracted the following information from each
trial:
1. characteristics of trials: setting, design, method of data-
analysis;
2. participants: study population, number of participants in
each group, patient characteristics such as age and gender;
3. type of intervention used: dosage, route of administration,
duration of treatment and follow-up, compliance, co-
interventions; and
4. outcomes: resolution or improvement of any patient-related
symptoms, adverse events related to the intervention, drop-outs
and reason(s) for dropping out.
Assessment of risk of bias in included studies
In the first publication of this review (Venekamp 2011), two re-
view authors (RV, MT) independently assessed the methodolog-
ical quality. For this 2014 update, two review authors (GH, PG)
independently assessed the methodological quality. Any disagree-
ments were resolved by discussion. Methodological quality assess-
ment of the included studies was based on random sequence gen-
eration, allocation concealment, blinding, completeness of data
and outcome assessment. Results of the ’Risk of bias’ assessment
are presented in the ’Risk of bias’ tables (Higgins 2011). The over-
all risk of bias is summarised graphically in Figure 1.
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Figure 1. ’Risk of bias’ summary
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Measures of treatment effect
We performed intention-to-treat (ITT) analyses. We categorised
the primary outcome (proportion of participants with resolution
or improvement of individual clinical features) into short-term
(two weeks or less) and long-term (more than two weeks). We
expressed dichotomous outcomes as risk ratio (RR) and risk dif-
ference (RD) and calculated 95% confidence intervals (CIs).
Dealing with missing data
We tried to contact the trial authors to provide additional infor-
mation in case of missing data. In primary analyses, we only anal-
ysed the available data based on the ITT principle. We explored
the impact of the incomplete data reporting on the validity of our
results by performing scenario analyses (best and worst-case sce-
nario). In the best-case scenario analyses all participants who were
lost to follow-up in the treatment group were counted as treat-
ment successes and all participants lost to follow-up in the control
group were counted as treatment failures. In contrast, in the worst-
case scenario analyses all participants who were lost to follow-up
in the treatment group were counted as treatment failures and all
participants lost to follow-up in the control group were counted
as treatment successes.
Assessment of heterogeneity
We assessed clinical heterogeneity of the trials by reviewing differ-
ences across trials in study population, setting, intervention and
outcome measures used. We used the I2 statistic to measure the
level of statistical heterogeneity for each outcome, with I2 val-
ues over 50% suggesting substantial heterogeneity (Higgins 2003;
Higgins 2011). We planned to consider five specific subgroups for
subgroup analysis a priori (see Subgroup analysis and investigation
of heterogeneity). We also performed sensitivity analyses by re-
moving single trials to investigate the extent to which they con-
tributed to the heterogeneity, particularly looking at reasons for
clinical heterogeneity among the studies (e.g. type of control treat-
ment).
Assessment of reporting biases
We assessed reporting biases using funnel plots (Figure 2).
Figure 2. Funnel plot of comparison: 1 Oral corticosteroids versus placebo or NSAID, outcome: 1.1
Proportion of patients with resolution or improved symptoms at days 3 to 7.
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Subgroup analysis and investigation of heterogeneity
We planned to consider subgroup analyses for the following areas,
if sufficient data were available:
1. adult/child;
2. type and route of delivery of corticosteroid;
3. duration and dose of corticosteroid;
4. radiological improvement versus clinical improvement; and
5. radiological versus clinical diagnosis.
We used a fixed-effect meta-analysis where no heterogeneity was
present. If statistical heterogeneity was detected but unresolved by
subgroup or sensitivity analysis, we used a random-effects model
to provide a more conservative effect estimate.
Sensitivity analysis
We performed sensitivity analyses by removing single trials to in-
vestigate the extent to which they contributed to the heterogene-
ity, particularly looking at reasons for clinical heterogeneity of the
studies (e.g. type of control treatment).
R E S U L T S
Description of studies
Results of the search
This is an update of a Cochrane review first published in 2011
(Venekamp 2011). In the first version of our review, we retrieved a
total of 2630 records from the initial search of CENTRAL,MED-
LINE and EMBASE. Removing duplicates left 1710 records. Af-
ter screening titles and abstracts, we identified seven potentially
eligible studies. We obtained their full-text papers and excluded
three trials as they studied chronic sinusitis (Ozturk 2011; Remer
2005; Vaidyanathan 2011). This left four trials eligible for inclu-
sion (Cannoni 1990; Gehanno 2000; Klossek 2004; Ratau 2004).
We identified no additional eligible trials after scanning the refer-
ence lists of full-text papers.
For this 2014 update, we retrieved a total of 630 records from
the initial search of CENTRAL, MEDLINE, EMBASE, DARE
and NHS EED. Removing duplicates left 529. After screening
titles and abstracts we identified one potentially eligible study (
Venekamp 2012a). Based on full-text evaluation, we included this
trial in our review as it fulfilled our predefined criteria. We did not
identify any ongoing trials.
Included studies
Five trials with a total of 1193 participants involved adults only
(Cannoni 1990; Gehanno 2000; Ratau 2004; Klossek 2004;
Venekamp 2012a). One trial was a 2 x 2 factorial design (Gehanno
2000) and the other four were parallel designs (Cannoni 1990;
Klossek 2004; Ratau 2004; Venekamp 2012a). In all five trials
acute sinusitis was defined clinically. However, three trials also
included radiological assessment as part of their inclusion crite-
ria (Cannoni 1990; Gehanno 2000; Klossek 2004). Three studies
performed in France included participants recruited from ENT
outpatient clinics (Cannoni 1990; Gehanno 2000; Klossek 2004),
one trial performed in South Africa included participants recruited
from primary care clinics (Ratau 2004) and one trial included pa-
tients from primary care centres in the Netherlands (Venekamp
2012a).
Interventions in the trials included oral (methyl)prednisone (24
mg to 80mg) for three, five and seven days and oral betamethasone
1 mg for five days. The control group received a placebo in four
studies (Gehanno 2000; Klossek 2004; Ratau 2004; Venekamp
2012a) and a non-steroidal anti-inflammatory drug (NSAID)
in one study (Cannoni 1990). In four studies participants also
received oral antibiotics: amoxicillin-clavulanic acid (Gehanno
2000; Ratau 2004), cefpodoxime (Klossek 2004) or pristinamycin
(Cannoni 1990), while one trial investigated the effectiveness of
oral corticosteroid monotherapy (Venekamp 2012a).
The use of analgesics (i.e. acetaminophen/paracetamol) was in-
cluded as an outcomemeasure in two studies (Klossek 2004; Ratau
2004). No symptomatic relief medication was permitted in one
study (Cannoni 1990), while no information on the use of addi-
tional medications was provided in one trial (Gehanno 2000). In
one trial participants were allowed to use symptom relief medica-
tion (acetaminophen/paracetamol for as long as needed and xy-
lometazoline 0.1% nasal spray for seven days).
The included studies reported the proportion of participants with
therapeutic success on day seven (Cannoni 1990), proportions of
participants experiencing pain relief on day four (Gehanno 2000),
global response to treatment onday three andday 10 to12 (Klossek
2004), improvement of symptoms from day zero to day six and
the percentage of participants with physical signs present or absent
on day zero and day six (Ratau 2004), and resolution of symptoms
(including facial pain, nasal congestion, postnasal discharge and
total symptoms) on day seven and day 14 (outcome data on facial
pain/pressure at day 14 were not included in the original publica-
tion but were provided by the authors). All studies reported on the
number of adverse events. In two studies the adverse events were
reported both by patients (questionnaire) and investigator (at site
visits) (Cannoni 1990; Klossek 2004), while the adverse events
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in the other studies were reported by the investigator (Gehanno
2000) or the patients (Ratau 2004; Venekamp 2012a) only. For
more details on the outcome measures of the included studies see
the Characteristics of included studies table.
Excluded studies
We excluded three trials after reviewing the full text, as they studied
the effectiveness of systemic corticosteroids in participants with
chronic sinusitis (Ozturk 2011;Remer2005;Vaidyanathan 2011).
Risk of bias in included studies
We judged the methodological quality of the included trials to
be moderate in four trials (Cannoni 1990; Gehanno 2000; Ratau
2004; Klossek 2004) and high in one trial (Venekamp 2012a) (see
Figure 1). For details of the risk of bias in included studies see the
’Risk of bias’ table (Characteristics of included studies).
Allocation
All five studies stated that they used randomisation, but we
judged concealment of allocation to be adequate in only one trial
(Venekamp 2012a). The methods of randomisation were unclear
in three of the five trials (Cannoni 1990; Gehanno 2000; Klossek
2004). Additionally, only two trials reported baseline characteris-
tics of participants (Klossek 2004; Venekamp 2012a).
Blinding
We considered all five trials to be double-blinded, but in four trials
there were insufficient details to determine whether this referred
to participants, outcome assessors or study personnel (Cannoni
1990; Gehanno 2000; Ratau 2004; Klossek 2004).
Incomplete outcome data
Four trials reported the numbers of participants who failed to
complete the trial (Cannoni 1990; Gehanno 2000; Klossek 2004;
Venekamp 2012a), whereas in one trial this was not reported and it
was assumed that there were no drop-outs (Ratau 2004). The total
loss to follow-up was low and varied from 4% (Gehanno 2000),
6% (Venekamp 2012a), 7% (Cannoni 1990) to 8% (Klossek
2004). In two of these studies the number of participants whowere
lost to follow-up was higher in the treatment group (Gehanno
2000; Klossek 2004), whereas in the other trials the drop-out
rate was (slightly) higher in the control group (Cannoni 1990;
Venekamp 2012a).
Selective reporting
In one trial (Venekamp 2012a) risk of reporting bias was judged
low as pre-specified (primary and secondary) outcomes were listed
in a trial register prior to study enrollment. In the other four trials
(Cannoni 1990; Gehanno 2000; Klossek 2004; Ratau 2004) no
study protocol was identified.
Other potential sources of bias
Three studies used ITT analyses (Gehanno 2000; Klossek 2004;
Venekamp 2012a), while in the other two this was not clear
(Cannoni 1990; Ratau 2004). Additionally, one trial did not pro-
vide information on absolute numbers of patients with resolution
of symptoms as only percentages were reported (Ratau 2004).
No other potential sources of bias could be detected in the five
included trials.
Effects of interventions
See: Summary of findings for the main comparison Oral
corticosteroids versus placebo or NSAID for acute sinusitis
For numerical details see the Data and analyses section. We iden-
tified five studies that met our inclusion criteria, which included
a total number of 1193 participants (Cannoni 1990; Gehanno
2000; Klossek 2004; Ratau 2004; Venekamp 2012a). From these
trials, data from a total of 1116 participants could be extracted
for meta-analyses for the primary outcome. The main findings are
reported in Summary of findings for the main comparison.
Primary outcomes
1. Proportion of participants with resolution or
improvement of symptoms
Information on the primary outcome could be retrieved from all
five trials but at different time points. One trial reported global
response to treatment on both day three and days 10 to 12 (
Klossek 2004), whereas the four other trials reported the outcome
of interest at one point in time: the proportions of participants
experiencing pain relief on day four (Gehanno 2000), proportions
of participants with physical signs present or absent at day six (
Ratau 2004), therapeutic success at day seven (Cannoni 1990) and
the proportion of patients with resolution of facial pain/pressure
at day seven and day 14 (Venekamp 2012a). When combining
data from the five trials, we calculated two effect estimates for
the primary outcome, ranging from days three to seven (Cannoni
1990; Gehanno 2000; Klossek 2004; Ratau 2004; Venekamp
2012a) and days four to 14 (Cannoni 1990; Gehanno 2000;
Klossek 2004; Ratau 2004; Venekamp 2012a).
Participants treated with oral corticosteroids were more likely to
have short-term resolution or improvement of symptoms than
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those receiving the control treatment (placebo or non-steroidal
anti-inflammatory drugs (NSAIDs)) at days three to seven (risk
ratio (RR) 1.3, 95% confidence interval (CI) 1.1 to 1.6; risk dif-
ference (RD) 17%, 95% CI 6% to 29%) (Analysis 1.1; Figure 3)
and at days four to 14 (RR 1.2, 95% CI 1.0 to 1.5; RD 14%,
95% CI 1% to 27%) (Analysis 1.2; Figure 4). Subgroup analy-
ses revealed that oral corticosteroid monotherapy had no benefi-
cial effects (Figure 3; Figure 4). Statistical heterogeneity was high
in both of these analyses (I2 statistic ≥ 69%). We therefore per-
formed a sensitivity analysis by removing the trial with NSAIDs
as a control treatment (Cannoni 1990). Sensitivity analyses on the
four trials with a placebo as the control treatment showed a similar
direction of effect, but to a lesser extent, at days three to seven (RR
1.2, 95% CI 1.1 to 1.3; RD 11%, 95% CI 4% to 17%) (Analysis
2.1; Figure 5) and days four to 14 (RR 1.1, 95% CI 1.0 to 1.2;
RD 8%, 95% CI 2% to 13%) (Gehanno 2000; Klossek 2004;
Ratau 2004; Venekamp 2012a) (Analysis 2.2; Figure 6). Statistical
heterogeneity was lower in these sensitivity analyses (I2 statistic ≤
30%).
Figure 3. Forest plot of comparison: 1 Oral corticosteroids versus placebo or NSAID, outcome: 1.1
Proportion of patients with resolution or improved symptoms at days 3 to 7.
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Figure 4. Forest plot of comparison: 1 Oral corticosteroids versus placebo or NSAID, outcome: 1.2
Proportion of patients with resolution or improved symptoms at days 4 to 14.
Figure 5. Forest plot of comparison: 2 Sensitivity analysis - Oral corticosteroids versus placebo, outcome:
2.1 Proportion of patients with resolution or improved symptoms at days 3 to 7.
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Figure 6. Forest plot of comparison: 2 Sensitivity analysis - Oral corticosteroids versus placebo, outcome:
2.2 Proportion of patients with resolution or improved symptoms at days 4 to 14.
In scenario analyses, the best-case scenario did show increased
beneficial effect sizes of oral corticosteroids for short-term relief
(Analysis 3.1; Analysis 3.3; Analysis 4.1; Analysis 4.3), whereas the
worst-case scenario showed no statistically significant beneficial
effect of oral corticosteroids (Analysis 3.2; Analysis 3.4; Analysis
4.2; Analysis 4.4).
Only one trial reported on the long-term effects (more than two
weeks) of oral corticosteroids (Venekamp 2012a). At eight weeks,
the proportions of patients with resolution of facial pain/pressure
and total symptoms were higher in the placebo group than in the
oral corticosteroid monotherapy group, although the difference
was not statistically significant (absolute risk difference (RD) -
2.2%, 95% CI -12.6% to 8.1% and -9.9%, 95% CI -24.7% to
4.9%, respectively). No differences in the frequency of consulta-
tions for acute sinusitis between the oral corticosteroid monother-
apy group (18/88) and the placebo group (21/86) were observed.
In addition, neither of the groups differed significantly in the pro-
portion of patients who received prescriptions for antibiotics (17/
88 versus 16/86) or intranasal corticosteroids (6/88 versus 15/86).
Secondary outcomes
1. Time to resolution of symptoms
One trial reported this outcome (Venekamp 2012a). No statisti-
cally significant differences in median duration of symptoms were
observed between the oral corticosteroid monotherapy group and
the placebo group (facial pain/pressure 4.5 versus five days, nasal
congestion four versus four days, postnasal discharge 3.5 versus
three days, runny nose two days versus one day and total symp-
toms seven versus nine days), except for cough (two versus three
days, P = 0.046).
2. Bacteriological cure and relapse rates
No data on these outcomes could be extracted from the trials.
3. Adverse events
No serious adverse events related to drug use were reported in the
studies. There was no significant difference between the corticos-
teroid group and the placebo groups in the occurrence of mild
adverse events (for example, abdominal pain, diarrhoea) or dis-
continuation of study treatment due to adverse events (Gehanno
2000; Klossek 2004; Ratau 2004; Venekamp 2012a). In one trial,
seven adverse events were rated as severe by the patient: three in
the corticosteroid group (one diarrhoea, one acute gastroenteritis,
one abdominal pain) versus four in the placebo group (one vom-
iting, one abdominal pain, one neuralgia, one ear pain) (Ratau
2004). In the trial that used a NSAID as control group (Cannoni
1990), the number of adverse events was significantly higher in
theNSAID group (51 adverse events in 35 participants) compared
to the corticosteroid group (23 adverse events in 18 participants).
In addition, discontinuation of study participation due to adverse
events occurred in seven participants from the NSAID group ver-
sus none in the prednisolone group. For further details on adverse
events see Table 1.
Subgroup analysis
Subgroup analyses revealed that oral corticosteroid monother-
apy had no statistically significant beneficial effects compared to
placebo (Figure 3; Figure 4). We did not perform other subgroup
analyses as the included trials did not report data for these pre-
specified subgroups.
D I S C U S S I O N
Summary of main results
Five trials with a total of 1193 adult participants were included
in this review. When combining the results of these studies, acute
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sinusitis patients treated with oral corticosteroids were more likely
to have short-term improvement or resolution of symptoms than
those receiving control treatment (placebo or non-steroidal anti-
inflammatory drugs (NSAIDs)) at days three to seven (risk differ-
ence (RD) 17%) and days four to 14 (RD 14%). Moreover, side
effects of oral corticosteroids reported in these studies were limited
and mild.
Overall completeness and applicability of
evidence
Before applying these results to practice, there are important lim-
itations which might have had an impact on our results.
Only five studies with a limited number of participants met the
inclusion criteria for this review (Cannoni 1990; Gehanno 2000;
Klossek 2004; Ratau 2004; Venekamp 2012a). Participants in four
of the five included studies also received oral antibiotics (Cannoni
1990; Gehanno 2000; Klossek 2004; Ratau 2004). These trials re-
ported on short-term outcomes only (less than two weeks). More-
over, the majority of the included patients in this review has been
recruited in ENT outpatient clinics as only two of the five trials,
including 227 participants, were performed in a primary care set-
ting (Ratau 2004; Venekamp 2012a), and none of the trials re-
ported on relapse rates of acute sinusitis. One high-quality trial
investigated the effectiveness of oral corticosteroids as amonother-
apy in 185 patients in primary care (of which 174 were analysed)
(Venekamp 2012a). In contrast to the beneficial effects found in
the four trials that assessed the effectiveness of systemic corticos-
teroids as adjunctive treatment to antibiotics, this latter trial found
no statistically significant beneficial effects of systemic corticos-
teroids compared to placebo.
Quality of the evidence
We judged four included trials to be of moderate methodologi-
cal quality (Cannoni 1990; Gehanno 2000; Ratau 2004; Klossek
2004), which might have led to biased estimates of effect. All trials
stated that they were randomised and double-blinded but only
one trial adequately reported the blinding procedure (Venekamp
2012a) and only two trials contained an adequate report of the
generationof allocation sequence (Ratau 2004;Venekamp 2012a).
Moreover, four of the five trials performed complete-case analysis
(excluding participants whowere lost to follow-up from their anal-
ysis), which might have important implications for the validity of
their results since missing values are rarely completely at random.
To investigate the potential impact of the incomplete data report-
ing on our results, we performed scenario analysis (best and worse-
case scenarios). Scenario analyses showed that outcomes missing
in the trials might have introduced attrition bias since the worst-
case scenario showed no statistically significant beneficial effect of
oral corticosteroids.
Potential biases in the review process
There was some clinical heterogeneity among the included trials.
Acute sinusitis was defined clinically in all trials but the three trials
performed in ENT outpatient clinics also included radiological
assessment as part of their inclusion criteria. In addition, dura-
tion and dosage of the intervention (prednisolone for three, five
and seven days (24 mg to 80 mg) and betamethasone 1 mg for
five days), type of control treatment (one trial used non-steroidal
anti-inflammatory drugs (NSAIDs) as a control treatment) and
the follow-up time did vary across the studies. Additionally, all
trials used different outcome assessments, varying from pain relief
to global response to treatment. Combining multiple endpoints
might lead to invalid results (type 1 error). However, the results
of most of the separate studies are more or less equal. Further-
more, we performed subgroup analyses for trials with or without
co-treatment with antibiotics. Nevertheless, one could argue that
(statistical) heterogeneity in the primary analyses was too high to
present pooled results (I2 statistic ≥ 75%). However, the consis-
tency of the I2 statistic is known to be limited when only a few
studies are available and subjective assessment could be made. To
enhance the validity of our results, we performed additional anal-
yses on the four trials with placebo as the control treatment. These
analyses showed similar results to the primary analyses but with
low (statistical) heterogeneity (I2 statistic≤ 30%). In addition, we
assessed funnel plots for potential reporting biases in the primary
analysis (Figure 2). No asymmetry could be detected based on the
five included trials.
Agreements and disagreements with other
studies or reviews
No previous review on the use of systemic corticosteroids in acute
sinusitis has been performed. Two systematic reviews on intranasal
corticosteroids for acute sinusitis (with or without antibiotics) re-
ported only modest beneficial effect sizes (for every 100 patients
treated with intranasal corticosteroids, seven additional patients
had complete or marked symptom relief at 15 to 21 days (number
needed to treat to benefit (NNTB) = 15)) (Zalmanovici 2011)
and for every 100 patients treated, eight additional patients had
improvement or resolution of symptoms at 14 to 21 days (NNTB
= 13) (Hayward 2012a). Since we primarily evaluated the effects
of systemic corticosteroids on short-term relief (< 14 days), a valid
comparison between these reviews cannot be made. However, in a
subsequent randomised controlled trial, performed in the primary
care setting, intranasal corticosteroids as a monotherapy did not
provide an overall beneficial effect in short-term symptom relief
(Williamson 2007).
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Oral corticosteroids as a monotherapy appear to be ineffective for
adult patients with clinically diagnosed acute sinusitis. Current
data on the use of oral corticosteroids as an adjunctive therapy
to oral antibiotics are limited: almost all trials are performed in
secondary care and there is a significant risk of bias. This limited
evidence suggests that oral corticosteroids in combination with
antibiotics may be modestly beneficial for the short-term relief of
symptoms in acute sinusitis, with a number needed to treat to
benefit of seven for resolution or symptom improvement. Until
further high-quality trials prove oral corticosteroids to be beneficial
in patients with acute sinusitis, their use is not supported by robust
evidence.
Implications for research
The only high-quality trial included in this review, performed in
antibiotic-naive patients with clinically diagnosed acute sinusitis,
found no statistically significant beneficial effects of systemic cor-
ticosteroids compared to placebo (Venekamp 2012a). The risk
difference (RD) for the primary outcome (proportion of patients
with resolution of facial pain or pressure at day seven) was 6.7%
(95% confidence interval (CI) -7.9% to 21.2%). This finding is at
odds with our meta-analysis, which showed a benefit of oral corti-
costeroids on improvement or resolution of symptoms. The differ-
ence may reflect the fact that the effect of systemic corticosteroids
alone is less than the effect of treatment with both systemic cor-
ticosteroids and antibiotics (resolution or improvement of symp-
toms at days three to seven: risk ratio (RR) 1.4, 95% confidence
interval (CI) 1.1 to 1.8; risk difference (RD) 20%, 95% CI 6%
to 34% (Figure 3) and resolution or improvement of symptoms
at days four to 10: RR 1.3, 95% CI 1.0 to 1.7; RD 18%, 95% CI
3% to 33% (Figure 4)), or that Venekamp 2012a may have been
underpowered to detect a small beneficial effect of systemic corti-
costeroids. However, the four trials included in our meta-analysis
that assessed oral corticosteroids in combination with antibiotics
have a significant risk of bias (see Quality of the evidence) and
therefore its results should be interpreted with caution. A large
primary care factorial trial is needed to establish whether oral cor-
ticosteroids offer additional benefits to antibiotics alone in acute
sinusitis.
Three of the four trials comparing the effects of antibiotics and oral
corticosteroids to antibiotics alone included only patients with ra-
diologically confirmed acute sinusitis and this may have enhanced
the benefit seenwith systemic corticosteroids.Meta-analyses of the
effect of antibiotics in acute sinusitis have demonstrated different
results when radiological assessment was part of the inclusion crite-
ria, compared to clinical diagnosis alone (Ahovuo-Saloranta 2011;
Young 2008). As such, we recommend that a computer tomogra-
phy (CT) scan should be performed at baseline in all patients par-
ticipating in a future primary care-based factorial trial on the effec-
tiveness of oral corticosteroids and antibiotics, in order to derive
a diagnostic model of patient characteristics, clinical signs, symp-
toms and additional point-of-care tests, which can accurately dis-
criminate between a positive and negative CT scan (Damoiseaux
2008). If a simple and feasible prediction model could be derived,
this may provide guidance to future studies evaluating the benefits
of antibiotics, corticosteroids or both in a subgroup of patients
with clinically diagnosed acute sinusitis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cannoni 1990
Methods Randomisation: yes, method of randomisation not described
Concealment of allocation: not described
Double-blind: yes, blinding procedure not described
Intention-to-treat (ITT): unclear
Loss to follow-up: described; 203 patients (93%) completed study
Design: parallel
Participants N: 219
Age: 15 to 70 years
Inclusion criteria: (sub)acute, non-allergic sinusitis confirmed by radiologic examina-
tion and nasal endoscopy
Exclusion criteria: allergic sinusitis (allergic rhinitis, nasal polyposis), previous sinonasal
surgery, contraindication to study treatment and treatment with corticosteroids, antibi-
otics or NSAIDs in 15 days preceding recruitment
Baseline characteristics: not described
Participants recorded symptoms twice a day and were examined at day 0 and day 7 of
treatment
Interventions All participants in both groups received pristinamycin (antibiotic) 1000 mg twice daily
Tx: prednisolone 40 mg once daily for participants with a weight < 60 kg and pred-
nisolone 60 mg once daily for participants with a weight > 60 kg, for 7 days; N = 107
(N = 103 included in analysis)
C group: niflumic acid (NSAID) 250 mg 3 daily for 7 days; N = 112 (N = 100 included
in analysis)
Use of additional medication: other anti-inflammatory drugs, intranasal medication
and analgesics were not permitted
Outcomes Primary outcome: therapeutic success, defined as a combination of resolution of spon-
taneous pain, absence of sinus pain on palpation, absence of nasal discharge or nasal
discharge without purulence and a clean appearance of the middle meatus at nasal en-
doscopy at day 7 of treatment
Secondary outcome: adverse events
Notes Setting: secondary care setting in France, 50 otorhinolaryngologists
Drop-outs total: 16/219 (7%)
Drop-outs from Tx: 4 (3.7%) - 4 loss to follow-up
Drop-outs from C group: 12 (12.7%): 2 loss to follow-up, 7 adverse events, 3 ineffec-
tiveness
Source of funding: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
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Cannoni 1990 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation method not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding procedure not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete-case analysis performed
Selective reporting (reporting bias) Unclear risk Study protocol not identified
Other bias Unclear risk ITT analysis - unclear. Baseline characteris-
tics - not described. Use of analgesics - not
permitted
Gehanno 2000
Methods Randomisation: yes, method of randomisation not described
Concealment of allocation: not described
Double-blind: yes, blinding procedure not described
Intention-to-treat (ITT): yes
Loss to follow-up: described; 417 patients (96%) completed study
Design: 2 x 2 factorial design
Participants N: 433
Age: 18 years or older
Inclusion criteria: less than 10 days of acute sinusitis defined by craniofacial pain,
purulent nasal discharge with purulent drainage from the middle meatus, and opacities
with or without air-fluid levels on standard X-ray or CT scan
Exclusion criteria: acute sinusitis requiring immediate surgical drainage, acute exac-
erbations of chronic sinusitis, contraindication to study treatment and treatment with
antibiotics or corticosteroids in 15 days preceding recruitment
Baseline characteristics: not described
Participants were contacted by telephone on day 4 +/-1 to evaluate craniofacial pain,
nasal discharge and temperature. A clinical and radiological follow-up was performed
on day 14 +/- 2, including an assessment of safety. Finally, the patient was contacted
again by telephone on day 30 +/- 2 to evaluate craniofacial pain, nasal discharge and
temperature
Interventions From days 0 to 5, all participants received amoxicillin-clavulanic acid (ACA) 500 mg 3
times a day
From days 0 to 5, participants randomised to either:
Tx:methylprednisolone 8 mg 3 times daily; N = 219 (N = 208 included in ITT analysis)
, or
C group: placebo; N = 214 (N = 209 included in ITT analysis)
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Gehanno 2000 (Continued)
From days 6 to 10, participants randomly received either ACA 500 mg 3 times a day or
placebo
Use of additional medication: not described
Outcomes Primary outcome: therapeutic success, defined as clinical recovery on day 14, with or
without radiological normalisation. The other cases were considered failures
Secondary outcomes: i) course of symptoms on day 4 ii) symptoms and possible radi-
ological signs on day 30
The study was primarily designed to determine the optimal duration of antibiotic treat-
ment by comparing various durations of treatment with ACA. As the effectiveness of
short-course corticosteroid was of secondary interest in this study, only data on day 4 of
treatment are provided
Notes Setting: secondary care setting in France, 51 otorhinolaryngologists
Drop-outs total: 16/433 (4%) - lack of data 13; protocol violation 3
Drop-outs from Tx: 11 (5.0%)
Drop-outs from C group: 5 (2.3%)
Source of funding: commercial - SmithKline Beecham
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding procedure not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Complete-case analysis performed
Selective reporting (reporting bias) Unclear risk Study protocol not identified
Other bias Unclear risk ITT analysis - yes. Baseline characteristics
- not described. Use of analgesics - not de-
scribed
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Klossek 2004
Methods Randomisation: yes, method of randomisation not described
Concealment of allocation: not described
Double-blind: yes, blinding procedure not described
Intention-to-treat (ITT): yes
Loss to follow-up: yes, reasons not described; 289 participants (92%) completed study
Design: parallel
Participants N: 314
Age: 18 years or older
Inclusion criteria: acute sinusitis, confirmed by X-ray and nasal endoscopy, for less than
5 days, with spontaneous pain assessed as > 50 mm on a visual analogue scale (VAS)
Exclusion criteria: acute sinusitis requiring immediate surgical drainage, allergic rhini-
tis, nasal polyposis, contraindication to study treatment, treatment with antibiotics in
previous 3 months or (intranasal or systemic) corticosteroids in 3 days preceding recruit-
ment
Baseline characteristics: balanced
Patients underwent X-ray and nasal endoscopic examination at day 1, day 10 to 12 and
day 28 to 32. Participants recorded symptoms from day 1 to 3 and were contacted by
telephone on day 4
Interventions All participants received cefpodoxime (antibiotic) 200 mg twice daily from days 1 to 10
Tx: prednisone 0.8 to 1.2 mg/kg (weight 40 to 60 kg: 40 mg, weight 60 to 80 kg: 60
mg, weight > 80 kg: 80 mg) for 3 days; N = 157 (N = 142 included in ITT analysis)
C group: placebo; N = 157 (N = 147 included in ITT analysis)
Use of additional medication: paracetamol 1000 mg 8-hourly for pain as needed, other
symptomatic relief medication not described
Outcomes Primary outcome:mean of the differences between pain at baseline and day 3 measured
using the VAS (this was termed the mean pain intensity difference - MPID)
Secondary outcomes: i) mean of the differences in intensity of nasal obstruction, ii) time
lapse before the orally expressed relief of pain (pain relief intensity difference - PRID),
iii) administration of paracetamol during the first 3 days, iv) global effect of treatment
scored by patient at day 3, v) global effect of treatment scored by participant at day 10
to 12
Notes Setting: secondary care setting in France, 80 otorhinolaryngologists
Drop-outs total: 25/314 (8%) - reasons unknown
Drop-outs from Tx: 15 (9.5%)
Drop-outs from C group: 10 (6.4%)
Source of funding: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not described
Allocation concealment (selection bias) Unclear risk Not mentioned
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Klossek 2004 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding procedure not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for drop-outs not reported, com-
plete-case analysis performed
Selective reporting (reporting bias) Unclear risk Study protocol not identified
Other bias Low risk ITT analysis - yes. Baseline characteristics
- balanced. Use of analgesics - noted (sec-
ondary outcome)
Ratau 2004
Methods Randomisation: yes, computer-generated random numbers
Concealment of allocation: not described
Double-blind: yes, blinding procedure not described
Intention-to-treat (ITT): unclear
Loss to follow-up: not described
Design: parallel
Participants N: 42
Age: 29 years (mean age)
Inclusion criteria: clinically defined acute sinusitis for less than12weeks. Total symptom
score (7 symptoms, scored 0 to 3 severity, to maximum score of 21) was 6 or higher,
at least 1 nasal symptom had to be moderate or severe and purulent rhinorrhoea or
postnasal drip had to be present
Exclusion criteria: nasal polyposis, abnormalities of the nose, contraindication to study
treatment, treatment with antibiotics, anti-inflammatory agents, oral corticosteroids in
previous 4 weeks or intranasal corticosteroids in 2 weeks preceding recruitment
Baseline characteristics: not described
Participants evaluated symptoms each evening for 5 days in a diary and recorded the use
of paracetamol and adverse events. Investigator scored signs and symptoms on the day
of diagnosis (day 0) and on the second visit (day 6)
Interventions All participants received amoxicillin-clavulanic acid 625 mg 3 times a day for 5 days
Tx: betamethasone 1 mg orally once daily for 5 days; N = 21
C group: placebo; N = 21
Use of additional medication: analgesics permitted, paracetamol 1000 mg 6-hourly
for pain as needed, other symptomatic relief medication (i.e. oral decongestants, anti-
histamines and mucolytics) not permitted
Outcomes Primary outcome: improvement of symptoms from day 0 to day 6 (change in treatment
effects)
Secondary outcomes: i) percentage of participants with physical signs present or absent
on day 0 and day 6, ii) number of paracetamol tablets taken, iii) adverse events
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Ratau 2004 (Continued)
Notes Setting: 3 primary healthcare sites in Republic of South Africa, 2003
Drop-outs: not described
Source of funding: non-commercial (Department of Pharmacology, University of Pre-
toria); drugs were supplied by pharmaceutical companies (betamethasone - Schering-
Plough; amoxicillin-clavulanic acid - Rolab Pharmaceuticals)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation method - computed-gen-
erated random numbers
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding procedure not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Unclear risk Study protocol not identified
Other bias Unclear risk ITT analysis - unclear. Baseline-character-
istics - not described. Outcome measures -
only percentages, no absolute numbers pro-
vided. Use of analgesics - noted (secondary
outcome)
Venekamp 2012a
Methods Randomisation: yes, block randomisation using computer-generated random numbers
Concealment of allocation: adequate
Double-blind: yes
Intention-to-treat (ITT): yes
Loss to follow-up: described; 174 patients (94%) completed study
Design: parallel
Participants N: 185
Age: 18 years and older
Inclusion criteria: symptoms of acute sinusitis (at least 2 symptoms: 1 of either nasal
discharge (anterior or posterior nasal drip) or nasal congestion; the other of either facial
pain or pressure, or pain when masticating) for at least 5 days
Exclusion criteria: complicated course of acute sinusitis (i.e. orbital swelling, tempera-
ture ≥ 38.5 °C after 5 days of symptoms) recurrent sinusitis (≥ 2 episodes in the previ-
ous year), pregnancy, previous ENT surgery for malignant disease, contraindication to
treatment with corticosteroids and use of (intranasal or oral) corticosteroids in 4 weeks
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Venekamp 2012a (Continued)
preceding recruitment
Baseline characteristics: balanced
Participants recorded symptoms in a daily diary for 14 days and were examined at day
0 and day 14 of treatment. At the end of follow-up (8 weeks after randomisation),
physicians were asked to complete a final questionnaire about consultations in the past
6 weeks and patients were contacted by telephone by the study physician to complete a
questionnaire
Interventions Tx: prednisolone 30 mg once daily for 7 days; N = 93 (N = 88 included in analysis)
C group: placebo for 7 days; N = 92 (N = 86 included in analysis)
Use of additional medication: participants were allowed to take acetaminophen/parac-
etamol 500 mg (maximum of 6 tablets per day) for as long as needed and xylometazoline
0.1% nasal spray for 7 days
Outcomes Primary outcome: proportion of patients with resolution of facial pain/pressure at day
7 of treatment
Secondary outcome: the proportion of patients with resolution of other clinically rel-
evant symptoms on day 7, time to resolution of total symptoms (combined symptoms
of runny nose, postnasal discharge, nasal congestion, cough and facial pain), median
duration of symptoms, health-related quality of life and resumption of daily activities
(work or school)
Outcome data (proportion of patients with resolution of facial pain/pressure) at day 14
was not included in the original CMAJ publication but has been provided by the authors
Notes Setting: 54 primary care centres in the Netherlands
Drop-outs total: 11/185 (5.9%)
Drop-outs from Tx: 5/93 (5.4%) - 1 withdrawal from study, 3 no diary returned, 1
incomplete symptom reporting
Drop-outs from C group: 6/92 (6.5%): 1 withdrawal from study, 2 no diary returned,
3 incomplete symptom reporting
Source of funding: non-commercial, grant from the Netherlands Organisation for
Health Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
in blocks of 4
Allocation concealment (selection bias) Low risk Sealed, blind-sequenced medication con-
tainers were distributed to participating
practices. The containers were identifiable
only by randomisation code number. The
pharmacy department of the University
Medical Center Utrecht (independent of
the trial team) created the block randomi-
sation sequence using computer-generated
randomnumbers. The randomisation code
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Venekamp 2012a (Continued)
was kept at a locker in the pharmacy de-
partment throughout the study
Blinding (performance bias and detection
bias)
All outcomes
Low risk Sealed, blind-sequenced medication con-
tainers were distributed to participating
practices. The containers were identifiable
only by randomisation code number. The
randomisation code was kept at a locker in
the pharmacy department throughout the
study and was not broken until data collec-
tion was completed and blinded analyses
were performed. Study medications were
identical in taste and appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for drop-out reported. Primarily
complete-case analysis was performed but
in sensitivity analysis missing data were im-
puted using multiple imputation. Primary
and sensitivity analysis showed similar re-
sults
Selective reporting (reporting bias) Low risk Pre-specified (primary and secondary) out-
comes are listed in Netherlands Trial Reg-
ister, NTR1295
Other bias Low risk ITT analysis - yes. Baseline characteristics
- balanced. Use of analgesics - allowed
ACA: amoxicillin-clavulanic acid
C group: control group
CMAJ: Canadian Medical Association Journal
CT scan: computed tomography scan
ENT: ear, nose and throat
ITT: intention-to-treat
MPID: mean pain intensity difference
N: number
NSAID: non-steroidal anti-inflammatory drug
PRID: pain relief intensity difference
Tx: treatment
VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ozturk 2011 Chronic sinusitis
Remer 2005 Chronic sinusitis
Vaidyanathan 2011 Chronic sinusitis with nasal polyposis
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D A T A A N D A N A L Y S E S
Comparison 1. Oral corticosteroids versus placebo or NSAID
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients with
resolution or improved
symptoms at days 3 to 7
5 1043 Risk Ratio (M-H, Random, 95% CI) 1.33 [1.09, 1.62]
1.1 Co-treatment with
antibiotics
4 869 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.08, 1.81]
1.2 Corticosteroid
monotherapy
1 174 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.87, 1.44]
2 Proportion of patients with
resolution or improved
symptoms at days 4 to 14
5 1116 Risk Ratio (M-H, Random, 95% CI) 1.23 [1.02, 1.49]
2.1 Co-treatment with
antibiotics
4 945 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.04, 1.68]
2.2 Corticosteroid
monotherapy
1 171 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.85, 1.16]
Comparison 2. Sensitivity analysis - oral corticosteroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients with
resolution or improved
symptoms at days 3 to 7
4 840 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [1.07, 1.31]
2 Proportion of patients with
resolution or improved
symptoms at days 4 to 14
4 913 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [1.03, 1.19]
Comparison 3. Best and worst-case scenario - oral corticosteroids versus NSAID or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients with
resolution or improved
symptoms at days 3 to 7 -
best-case scenario
5 1193 Risk Ratio (M-H, Random, 95% CI) 1.62 [1.18, 2.23]
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2 Proportion of patients with
resolution or improved
symptoms at days 3 to 7 -
worst-case scenario
5 1193 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.77, 1.48]
3 Proportion of patients with
resolution or improved
symptoms at days 4 to 14 -
best-case scenario
5 1193 Risk Ratio (M-H, Random, 95% CI) 1.33 [1.11, 1.61]
4 Proportion of patients with
resolution or improved
symptoms at days 4 to 14 -
worst-case scenario
5 1193 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.92, 1.35]
Comparison 4. Best and worst-case scenario - oral corticosteroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients with
resolution or improved
symptoms at days 3 to 7 -
best-case scenario
4 974 Risk Ratio (M-H, Random, 95% CI) 1.50 [1.07, 2.11]
2 Proportion of patients with
resolution or improved
symptoms at days 3 to 7 -
worst-case scenario
4 974 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.68, 1.35]
3 Proportion of patients with
resolution or improved
symptoms at days 4 to 14 -
best-case scenario
4 974 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.10, 1.27]
4 Proportion of patients with
resolution or improved
symptoms at days 4 to 14 -
worst-case scenario
4 974 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.87, 1.14]
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Analysis 1.1. Comparison 1 Oral corticosteroids versus placebo or NSAID, Outcome 1 Proportion of
patients with resolution or improved symptoms at days 3 to 7.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 1 Oral corticosteroids versus placebo or NSAID
Outcome: 1 Proportion of patients with resolution or improved symptoms at days 3 to 7
Study or subgroup Oral corticosteroid Placebo or NSAID Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Co-treatment with antibiotics
Cannoni 1990 79/103 40/100 20.4 % 1.92 [ 1.47, 2.49 ]
Gehanno 2000 158/208 136/209 28.1 % 1.17 [ 1.03, 1.32 ]
Klossek 2004 60/103 49/104 20.5 % 1.24 [ 0.95, 1.61 ]
Ratau 2004 15/21 10/21 9.9 % 1.50 [ 0.89, 2.53 ]
Subtotal (95% CI) 435 434 78.8 % 1.40 [ 1.08, 1.81 ]
Total events: 312 (Oral corticosteroid), 235 (Placebo or NSAID)
Heterogeneity: Tau2 = 0.05; Chi2 = 12.03, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 2.57 (P = 0.010)
2 Corticosteroid monotherapy
Venekamp 2012a 55/88 48/86 21.2 % 1.12 [ 0.87, 1.44 ]
Subtotal (95% CI) 88 86 21.2 % 1.12 [ 0.87, 1.44 ]
Total events: 55 (Oral corticosteroid), 48 (Placebo or NSAID)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Total (95% CI) 523 520 100.0 % 1.33 [ 1.09, 1.62 ]
Total events: 367 (Oral corticosteroid), 283 (Placebo or NSAID)
Heterogeneity: Tau2 = 0.03; Chi2 = 12.87, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Chi2 = 1.50, df = 1 (P = 0.22), I2 =33%
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Analysis 1.2. Comparison 1 Oral corticosteroids versus placebo or NSAID, Outcome 2 Proportion of
patients with resolution or improved symptoms at days 4 to 14.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 1 Oral corticosteroids versus placebo or NSAID
Outcome: 2 Proportion of patients with resolution or improved symptoms at days 4 to 14
Study or subgroup Oral corticosteroid Placebo or NSAID Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Co-treatment with antibiotics
Cannoni 1990 79/103 40/100 18.0 % 1.92 [ 1.47, 2.49 ]
Gehanno 2000 158/208 136/209 24.6 % 1.17 [ 1.03, 1.32 ]
Klossek 2004 116/138 114/145 25.1 % 1.07 [ 0.96, 1.20 ]
Ratau 2004 15/21 10/21 8.9 % 1.50 [ 0.89, 2.53 ]
Subtotal (95% CI) 470 475 76.6 % 1.32 [ 1.04, 1.68 ]
Total events: 368 (Oral corticosteroid), 300 (Placebo or NSAID)
Heterogeneity: Tau2 = 0.04; Chi2 = 18.98, df = 3 (P = 0.00028); I2 =84%
Test for overall effect: Z = 2.29 (P = 0.022)
2 Corticosteroid monotherapy
Venekamp 2012a 69/87 67/84 23.4 % 0.99 [ 0.85, 1.16 ]
Subtotal (95% CI) 87 84 23.4 % 0.99 [ 0.85, 1.16 ]
Total events: 69 (Oral corticosteroid), 67 (Placebo or NSAID)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 557 559 100.0 % 1.23 [ 1.02, 1.49 ]
Total events: 437 (Oral corticosteroid), 367 (Placebo or NSAID)
Heterogeneity: Tau2 = 0.03; Chi2 = 22.92, df = 4 (P = 0.00013); I2 =83%
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Chi2 = 3.89, df = 1 (P = 0.05), I2 =74%
0.2 0.5 1 2 5
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Analysis 2.1. Comparison 2 Sensitivity analysis - oral corticosteroids versus placebo, Outcome 1 Proportion
of patients with resolution or improved symptoms at days 3 to 7.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 2 Sensitivity analysis - oral corticosteroids versus placebo
Outcome: 1 Proportion of patients with resolution or improved symptoms at days 3 to 7
Study or subgroup Oral corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Venekamp 2012a 55/88 48/86 20.0 % 1.12 [ 0.87, 1.44 ]
Klossek 2004 60/103 49/104 20.1 % 1.24 [ 0.95, 1.61 ]
Gehanno 2000 158/208 136/209 55.8 % 1.17 [ 1.03, 1.32 ]
Ratau 2004 15/21 10/21 4.1 % 1.50 [ 0.89, 2.53 ]
Total (95% CI) 420 420 100.0 % 1.19 [ 1.07, 1.31 ]
Total events: 288 (Oral corticosteroids), 243 (Placebo)
Heterogeneity: Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Sensitivity analysis - oral corticosteroids versus placebo, Outcome 2 Proportion
of patients with resolution or improved symptoms at days 4 to 14.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 2 Sensitivity analysis - oral corticosteroids versus placebo
Outcome: 2 Proportion of patients with resolution or improved symptoms at days 4 to 14
Study or subgroup Oral corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Venekamp 2012a 69/87 67/84 21.0 % 0.99 [ 0.85, 1.16 ]
Gehanno 2000 158/208 136/209 41.7 % 1.17 [ 1.03, 1.32 ]
Ratau 2004 15/21 10/21 3.1 % 1.50 [ 0.89, 2.53 ]
Klossek 2004 116/138 114/145 34.2 % 1.07 [ 0.96, 1.20 ]
Total (95% CI) 454 459 100.0 % 1.11 [ 1.03, 1.19 ]
Total events: 358 (Oral corticosteroids), 327 (Placebo)
Heterogeneity: Chi2 = 4.28, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Best and worst-case scenario - oral corticosteroids versus NSAID or placebo,
Outcome 1 Proportion of patients with resolution or improved symptoms at days 3 to 7 - best-case scenario.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 3 Best and worst-case scenario - oral corticosteroids versus NSAID or placebo
Outcome: 1 Proportion of patients with resolution or improved symptoms at days 3 to 7 - best-case scenario
Study or subgroup Oral corticosteroids Placebo or NSAID Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Venekamp 2012a 60/93 48/92 21.0 % 1.24 [ 0.97, 1.58 ]
Klossek 2004 114/157 49/157 20.9 % 2.33 [ 1.81, 2.99 ]
Gehanno 2000 169/219 136/214 23.1 % 1.21 [ 1.07, 1.38 ]
Ratau 2004 15/21 10/21 14.5 % 1.50 [ 0.89, 2.53 ]
Cannoni 1990 83/107 40/112 20.5 % 2.17 [ 1.66, 2.84 ]
Total (95% CI) 597 596 100.0 % 1.62 [ 1.18, 2.23 ]
Total events: 441 (Oral corticosteroids), 283 (Placebo or NSAID)
Heterogeneity: Tau2 = 0.11; Chi2 = 34.19, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.98 (P = 0.0029)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Best and worst-case scenario - oral corticosteroids versus NSAID or placebo,
Outcome 2 Proportion of patients with resolution or improved symptoms at days 3 to 7 - worst-case scenario.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 3 Best and worst-case scenario - oral corticosteroids versus NSAID or placebo
Outcome: 2 Proportion of patients with resolution or improved symptoms at days 3 to 7 - worst-case scenario
Study or subgroup Oral corticosteroids Placebo or NSAID Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Venekamp 2012a 55/93 54/92 20.8 % 1.01 [ 0.79, 1.28 ]
Klossek 2004 60/157 102/157 21.0 % 0.59 [ 0.47, 0.74 ]
Gehanno 2000 158/219 141/214 22.7 % 1.09 [ 0.96, 1.24 ]
Ratau 2004 15/21 10/21 14.5 % 1.50 [ 0.89, 2.53 ]
Cannoni 1990 79/107 52/112 21.0 % 1.59 [ 1.27, 2.00 ]
Total (95% CI) 597 596 100.0 % 1.07 [ 0.77, 1.48 ]
Total events: 367 (Oral corticosteroids), 359 (Placebo or NSAID)
Heterogeneity: Tau2 = 0.12; Chi2 = 39.86, df = 4 (P<0.00001); I2 =90%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Best and worst-case scenario - oral corticosteroids versus NSAID or placebo,
Outcome 3 Proportion of patients with resolution or improved symptoms at days 4 to 14 - best-case scenario.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 3 Best and worst-case scenario - oral corticosteroids versus NSAID or placebo
Outcome: 3 Proportion of patients with resolution or improved symptoms at days 4 to 14 - best-case scenario
Study or subgroup Oral corticosteroids Placebo or NSAID Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Venekamp 2012a 75/93 67/92 23.2 % 1.11 [ 0.94, 1.30 ]
Gehanno 2000 169/219 136/214 24.9 % 1.21 [ 1.07, 1.38 ]
Ratau 2004 15/21 10/21 8.8 % 1.50 [ 0.89, 2.53 ]
Cannoni 1990 83/107 40/112 17.8 % 2.17 [ 1.66, 2.84 ]
Klossek 2004 135/157 114/157 25.3 % 1.18 [ 1.06, 1.33 ]
Total (95% CI) 597 596 100.0 % 1.33 [ 1.11, 1.61 ]
Total events: 477 (Oral corticosteroids), 367 (Placebo or NSAID)
Heterogeneity: Tau2 = 0.03; Chi2 = 21.58, df = 4 (P = 0.00024); I2 =81%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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Analysis 3.4. Comparison 3 Best and worst-case scenario - oral corticosteroids versus NSAID or placebo,
Outcome 4 Proportion of patients with resolution or improved symptoms at days 4 to 14 - worst-case scenario.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 3 Best and worst-case scenario - oral corticosteroids versus NSAID or placebo
Outcome: 4 Proportion of patients with resolution or improved symptoms at days 4 to 14 - worst-case scenario
Study or subgroup Oral corticosteroids Placebo or NSAID Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Venekamp 2012a 69/93 75/92 22.9 % 0.91 [ 0.78, 1.06 ]
Gehanno 2000 158/219 141/214 24.1 % 1.09 [ 0.96, 1.24 ]
Ratau 2004 15/21 10/21 9.1 % 1.50 [ 0.89, 2.53 ]
Cannoni 1990 79/107 52/112 19.6 % 1.59 [ 1.27, 2.00 ]
Klossek 2004 116/157 126/157 24.3 % 0.92 [ 0.82, 1.04 ]
Total (95% CI) 597 596 100.0 % 1.11 [ 0.92, 1.35 ]
Total events: 437 (Oral corticosteroids), 404 (Placebo or NSAID)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.86, df = 4 (P = 0.00009); I2 =83%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Best and worst-case scenario - oral corticosteroids versus placebo, Outcome 1
Proportion of patients with resolution or improved symptoms at days 3 to 7 - best-case scenario.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 4 Best and worst-case scenario - oral corticosteroids versus placebo
Outcome: 1 Proportion of patients with resolution or improved symptoms at days 3 to 7 - best-case scenario
Study or subgroup Oral corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Venekamp 2012a 60/93 48/92 26.4 % 1.24 [ 0.97, 1.58 ]
Klossek 2004 114/157 49/157 26.3 % 2.33 [ 1.81, 2.99 ]
Gehanno 2000 169/219 136/214 29.5 % 1.21 [ 1.07, 1.38 ]
Ratau 2004 15/21 10/21 17.7 % 1.50 [ 0.89, 2.53 ]
Total (95% CI) 490 484 100.0 % 1.50 [ 1.07, 2.11 ]
Total events: 358 (Oral corticosteroids), 243 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 23.12, df = 3 (P = 0.00004); I2 =87%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Best and worst-case scenario - oral corticosteroids versus placebo, Outcome 2
Proportion of patients with resolution or improved symptoms at days 3 to 7 - worst-case scenario.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 4 Best and worst-case scenario - oral corticosteroids versus placebo
Outcome: 2 Proportion of patients with resolution or improved symptoms at days 3 to 7 - worst-case scenario
Study or subgroup Oral corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Venekamp 2012a 55/93 54/92 26.4 % 1.01 [ 0.79, 1.28 ]
Klossek 2004 60/157 102/157 26.7 % 0.59 [ 0.47, 0.74 ]
Gehanno 2000 158/219 141/214 29.1 % 1.09 [ 0.96, 1.24 ]
Ratau 2004 15/21 10/21 17.8 % 1.50 [ 0.89, 2.53 ]
Total (95% CI) 490 484 100.0 % 0.96 [ 0.68, 1.35 ]
Total events: 288 (Oral corticosteroids), 307 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 25.47, df = 3 (P = 0.00001); I2 =88%
Test for overall effect: Z = 0.23 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Best and worst-case scenario - oral corticosteroids versus placebo, Outcome 3
Proportion of patients with resolution or improved symptoms at days 4 to 14 - best-case scenario.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 4 Best and worst-case scenario - oral corticosteroids versus placebo
Outcome: 3 Proportion of patients with resolution or improved symptoms at days 4 to 14 - best-case scenario
Study or subgroup Oral corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Venekamp 2012a 75/93 67/92 21.4 % 1.11 [ 0.94, 1.30 ]
Gehanno 2000 169/219 136/214 35.3 % 1.21 [ 1.07, 1.38 ]
Ratau 2004 15/21 10/21 2.0 % 1.50 [ 0.89, 2.53 ]
Klossek 2004 135/157 114/157 41.3 % 1.18 [ 1.06, 1.33 ]
Total (95% CI) 490 484 100.0 % 1.18 [ 1.10, 1.27 ]
Total events: 394 (Oral corticosteroids), 327 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.64, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.46 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Best and worst-case scenario - oral corticosteroids versus placebo, Outcome 4
Proportion of patients with resolution or improved symptoms at days 4 to 14 - worst-case scenario.
Review: Systemic corticosteroids for acute sinusitis
Comparison: 4 Best and worst-case scenario - oral corticosteroids versus placebo
Outcome: 4 Proportion of patients with resolution or improved symptoms at days 4 to 14 - worst-case scenario
Study or subgroup Oral corticosteroids Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Venekamp 2012a 69/93 75/92 28.5 % 0.91 [ 0.78, 1.06 ]
Gehanno 2000 158/219 141/214 32.5 % 1.09 [ 0.96, 1.24 ]
Ratau 2004 15/21 10/21 5.7 % 1.50 [ 0.89, 2.53 ]
Klossek 2004 116/157 126/157 33.3 % 0.92 [ 0.82, 1.04 ]
Total (95% CI) 490 484 100.0 % 1.00 [ 0.87, 1.14 ]
Total events: 358 (Oral corticosteroids), 352 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.60, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Adverse events
Study Intervention Comparison Side effects Comments
Cannoni 1990 Prednisolone 40 mg once
daily for participants with
a weight < 60 kg and
prednisolone 60 mg once
daily for participants with
a weight > 60 kg for 7 days
Niflumic acid (NSAID)
250 mg 3 daily for 7 days
Nausea, vomiting, gastric
complaints
Adverse events
NSAID group versus cor-
ticosteroid group: 51 ver-
sus 23 (P < 0.05)
Discontin-
uation of study participa-
tion due to adverse events
NSAID group versus cor-
ticosteroid group: 7 versus
0 (P < 0.05)
Gehanno 2000 Methylprednisolone 8 mg
3 daily for 5 days
Placebo Nausea, vomiting, diar-
rhoea, gastric pain, skin re-
actions and candidal su-
perinfection
Intercurrent events cor-
ticosteroid group versus
placebo group: 24 (11%)
versus 22 (10%)
44Systemic corticosteroids for acute sinusitis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Adverse events (Continued)
Dis-
continuation of treatment
due to intercurrent events
corticosteroid group ver-
sus placebo group: 5 ver-
sus 3
Klossek 2004 Prednisone 0.8 to 1.2 mg/
kg (weight 40 to 60 kg: 40
mg, weight 60 to 80 kg:
60 mg, weight > 80 kg: 80
mg) for 3 days
Placebo Vomiting, diarrhoea ab-
dominal pain, allergic re-
action
46 adverse events were
noted; no statistical differ-
ence between the groups
7/46 were rated as severe
by the patient: 3 in cor-
ticosteroid group (1 diar-
rhoea, 1 acute gastroen-
teritis, 1 abdominal pain)
versus 4 in placebo group
(1 vomiting, 1 abdominal
pain, 1 neuralgia, 1 ear
pain)
5 adverse events are pos-
sibly related to the treat-
ment: 4 in corticosteroid
group (diarrhoea, acute
gastroenteritis, abdominal
pain, allergic reaction) and
1 in placebo group (mod-
erate colitis)
Ratau 2004 Betamethasone 1
mg orally once daily for 5
days
Placebo No adverse events re-
ported
No adverse events or erup-
tions of new diseases as-
sociated with the use of
betamethasone were re-
ported
2 adverse reactions were
reported in the placebo
group: cough and macu-
lopapular rash
Venekamp 2012a Prednisolone 30 mg orally
once daily for 7 days
Placebo Gastric complaints, diar-
rhoea, increased appetite,
mood disturbance, sleep
disturbance
No statistically significant
differences were observed
between groups at either 1
or 2 weeks
In total, 2 serious adverse
events not related to drug
use were reported: 1 hospi-
tal admission for anaemia
on day 49 of the study
in the placebo group and
1 hospital admission for
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Table 1. Adverse events (Continued)
wasp sting-induced ana-
phylaxis on day 28 of the
study in the prednisolone
group
NSAID: non-steroidal anti-inflammatory drug
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) and CENTRAL search strategy
1 exp Sinusitis/
2 sinusit*.tw.
3 (rhinosinusit* or nasosinusit*).tw.
4 ((sinus* or paranasal or para-nasal or nasopharynx or naso-pharynx) adj3 (infect* or inflam*)).tw.
5 purulent nasal discharge*.tw.
6 (nasal adj3 obstruct*).tw.
7 Rhinitis/
8 rhinit*.tw.
9 or/1-8
10 Adrenal Cortex Hormones/
11 corticosteroid*.tw,nm.
12 exp Glucocorticoids/
13 exp Hydroxycorticosteroids/
14 exp Pregnenediones/
15 hydrocortisone.tw,nm.
16 hydroxypregnenolone.tw,nm.
17 pregnenolone.tw,nm.
18 tetrahydrocortisol.tw,nm.
19 cortodoxone.tw,nm.
20 cortisone.tw,nm.
21 corticosterone.tw,nm.
22 hydroxycorticosteroid*.tw,nm.
23 glucocorticoid*.tw,nm.
24 triamcinolone.tw,nm.
25 prednisone.tw,nm.
26 prednisolone.tw,nm.
27 paramethasone.tw,nm.
28 methylprednisolone.tw,nm.
29 dexamethasone.tw,nm.
30 clobetasol.tw,nm.
31 beclomethasone.tw,nm.
32 betamethasone.tw,nm.
33 budesonide.tw,nm.
34 steroid*.tw,nm.
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35 (efcortesol or hydrocortone or solu-cortef ).tw,nm.
36 (betnelan or betnesol).tw,nm.
37 (deflazacort or calcort).tw,nm.
38 (medrone or solu-medrone or depo-medrone).tw,nm.
39 kenalog.tw,nm.
40 (novolizer or pulmicort or symbicort).tw,nm.
41 (beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte).tw.
42 or/10-41
43 9 and 42
Appendix 2. EMBASE.com search strategy
47. #43 AND #46
46. #44 OR #45
45. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR ’cross-over’:ab,ti OR volunteer*:
ab,ti OR allocat*:ab,ti OR assign*:ab,ti OR ((singl* OR doubl*) NEAR/2 (mask* OR blind*)):ab,ti
44. ’randomised controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
43. #10 AND #42
42. #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40
OR #41
41. aerobec:ab,ti OR asmabec:ab,ti OR beclazone:ab,ti OR becodisks:ab,ti OR becotide:ab,ti OR qvar:ab,ti OR becloforte:ab,ti OR
’clenil modulite’:ab,ti
40. novolizer:ab,ti OR pulmicort:ab,ti OR symbicort:ab,ti
39. kenalog:ab,ti AND [embase]/lim
38. medrone:ab,ti OR ’solu medrone’:ab,ti OR ’depo medrone’:ab,ti
37. deflazacort:ab,ti OR calcort:ab,ti
36. betnelan:ab,ti OR betnesol:ab,ti
35. efcortesol:ab,ti OR hydrocortone:ab,ti OR ’solu cortef ’:ab,ti
34. steroid:ab,ti
33. budesonide:ab,ti
32. betamethasone:ab,ti
31. beclomethasone:ab,ti OR beclometasone:ab,ti
30. clobetasol:ab,ti
29. dexamethasone:ab,ti
28. methylprednisolone:ab,ti
27. paramethasone:ab,ti
26. prednisolone:ab,ti
25. prednisone:ab,ti
24. triamcinolone:ab,ti
23. glucocorticoid*:ab,ti
22. hydroxycorticosteroid*:ab,ti
21. corticosterone:ab,ti
20. cortisone:ab,ti
19. cortodoxone:ab,ti
18. tetrahydrocortisol:ab,ti
17. pregnenolone:ab,ti
16. hydroxypregnenolone:ab,ti
15. hydrocortisone:ab,ti
14. pregnenedione*:ab,ti
13. ’glucocorticoid’/exp OR ’hydroxycorticosteroid’/de OR ’pregnane derivative’/de
12. corticosteroid*:ab,ti
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11. ’corticosteroid’/de
10. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9
9. rhinit*:ab,ti
8. ’rhinitis’/de
7. (nasal NEAR/3 obstruct*):ab,ti
6. ’purulent nasal discharge’:ab,ti
5. ((sinus* OR paranasal OR ’para nasal’ OR nasopharynx OR ’naso pharynx’) NEAR/3 (infect* OR inflam*)):ab,ti
4. rhinosinusit*:ab,ti OR nasosinusit*:ab,ti
3. ’rhinosinusitis’/de
2. sinusit*:ab,ti
1. ’sinusitis’/exp
WH A T ’ S N E W
Last assessed as up-to-date: 19 February 2014.
Date Event Description
19 February 2014 New citation required but conclusions have not
changed
Oral corticosteroids as amonotherapy appear to be inef-
fective for adult patients with clinically diagnosed acute
sinusitis. Current data on the use of oral corticosteroids
as an adjunctive therapy to oral antibiotics are limited:
almost all trials are performed in secondary care and
there is a significant risk of bias. This limited evidence
suggests that oral corticosteroids in combination with
antibiotics may be modestly beneficial for short-term
relief of symptoms in acute sinusitis, with a number
needed to treat to benefit of seven for resolution or im-
provement of symptoms. A large primary care factorial
trial is needed to establish whether oral corticosteroids
offer additional benefits over antibiotics in acute sinusi-
tis
19 February 2014 New search has been performed We updated the searches in February 2014. One new
trial was identified (Venekamp 2012a). This study in-
cluded adults with clinically diagnosed acute sinusi-
tis in primary care and assessed the effectiveness of a
short course of oral corticosteroids (prednisolone 30
mg/day for seven days) as a monotherapy compared to
placebo. We judged the risk of bias to be low. This trial
provided data on resolution of facial pain/pressure and
other symptoms at day seven, day 14 and eight weeks,
time lapse before resolution of symptoms and adverse
events. Systemic corticosteroid monotherapy appeared
to be ineffective for adult patients with clinically diag-
nosed acute sinusitis
We did not identify any ongoing trials.
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C O N T R I B U T I O N S O F A U T H O R S
Gail Hayward drafted the protocol. The manuscript was reviewed by all of the review authors.
D E C L A R A T I O N S O F I N T E R E S T
Roderick P. Venekamp and Maroeska M. Rovers were involved in the PRET (Prednisolone Rhinosinusitis Efficacy Trial) study entitled
’Optimal treatment of rhinosinusitis-like symptoms: double-blind placebo controlled randomised study with prednisolone versus usual
care treatment’ (Venekamp 2012a). This trial has been included in this 2014 update. To avoid any potential conflicts of interest, two
other review authors (Gail Hayward, Paul Glasziou) performed ’Risk of bias’ assessment and data extraction for this trial.
Maroeska M. Rovers has participated in a workshop and educational activities on otitis media organised by GlaxoSmithKline and
received a grant from GlaxoSmithKline for a study on the microbiology of otitis media in 2009.
Paul Glasziou is an investigator on a five-year National Health and Medical Research Council (NHMRC) grant looking at antibiotic
prescribing and resistance. He is on the board of Therapeutic Guidelines Ltd, which produces the Antibiotic Guidelines booklet.
Matthew J Thompson, Gail Hayward, Carl J Heneghan, Chris B Del Mar and Rafael Perera: none known.
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